NasdaqGS - Delayed Quote USD

Karyopharm Therapeutics Inc. (KPTI)

1.0600 0.0000 (0.00%)
At close: April 26 at 4:00 PM EDT
1.0900 +0.03 (+2.83%)
After hours: April 26 at 6:54 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
146,033.0000
146,033.0000
157,074.0000
209,819.0000
108,085.0000
Cost of Revenue
4,942.0000
4,942.0000
5,213.0000
3,402.0000
2,705.0000
Gross Profit
141,091.0000
141,091.0000
151,861.0000
206,417.0000
105,380.0000
Operating Expense
270,631.0000
270,631.0000
294,063.0000
304,688.0000
277,230.0000
Operating Income
-129,540.0000
-129,540.0000
-142,202.0000
-98,271.0000
-171,850.0000
Net Non Operating Interest Income Expense
-12,880.0000
-12,880.0000
-22,637.0000
-25,464.0000
-24,320.0000
Other Income Expense
-356.0000
-356.0000
-83.0000
-85.0000
206.0000
Pretax Income
-142,776.0000
-142,776.0000
-164,922.0000
-123,820.0000
-195,964.0000
Tax Provision
323.0000
323.0000
369.0000
268.0000
309.0000
Net Income Common Stockholders
-143,099.0000
-143,099.0000
-165,291.0000
-124,088.0000
-196,273.0000
Diluted NI Available to Com Stockholders
-143,099.0000
-143,099.0000
-165,291.0000
-124,088.0000
-196,273.0000
Basic EPS
-1.31
-1.25
-2.02
-1.65
-2.72
Diluted EPS
-1.31
-1.25
-2.02
-1.65
-2.72
Basic Average Shares
108,031.0000
114,221.0000
81,871.0000
75,218.0000
72,044.0000
Diluted Average Shares
108,031.0000
114,221.0000
81,871.0000
75,218.0000
72,044.0000
Total Operating Income as Reported
-129,540.0000
-129,540.0000
-142,202.0000
-98,271.0000
-171,850.0000
Total Expenses
275,573.0000
275,573.0000
299,276.0000
308,090.0000
279,935.0000
Net Income from Continuing & Discontinued Operation
-143,099.0000
-143,099.0000
-165,291.0000
-124,088.0000
-196,273.0000
Normalized Income
-143,099.0000
-143,099.0000
-165,291.0000
-124,088.0000
-196,423.3800
Interest Income
10,943.0000
10,943.0000
2,359.0000
582.0000
2,820.0000
Interest Expense
23,823.0000
23,823.0000
24,996.0000
26,046.0000
27,140.0000
Net Interest Income
-12,880.0000
-12,880.0000
-22,637.0000
-25,464.0000
-24,320.0000
EBIT
-118,953.0000
-118,953.0000
-139,926.0000
-97,774.0000
-168,824.0000
EBITDA
-118,423.0000
-118,423.0000
-139,305.0000
-96,985.0000
-167,852.0000
Reconciled Cost of Revenue
4,942.0000
4,942.0000
5,213.0000
3,402.0000
2,705.0000
Reconciled Depreciation
530.0000
530.0000
621.0000
789.0000
972.0000
Net Income from Continuing Operation Net Minority Interest
-143,099.0000
-143,099.0000
-165,291.0000
-124,088.0000
-196,273.0000
Total Unusual Items Excluding Goodwill
--
--
-96.0000
-110.0000
206.0000
Total Unusual Items
--
--
-96.0000
-110.0000
206.0000
Normalized EBITDA
-118,423.0000
-118,423.0000
-139,305.0000
-96,985.0000
-168,058.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
--
--
--
--
55.6200
12/31/2020 - 11/6/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

FGEN FibroGen, Inc.
1.0400
+1.96%
 
HRTX Heron Therapeutics, Inc.
2.4500
-3.92%
 
CLSD Clearside Biomedical, Inc.
1.3400
+6.35%
 
CARA Cara Therapeutics, Inc.
0.6843
-2.24%
 
TSVT 2seventy bio, Inc.
4.2550
-0.82%
 
LPTX Leap Therapeutics, Inc.
3.2500
+2.52%
 
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
 
MGNX MacroGenics, Inc.
14.56
+1.32%
 
ADAP Adaptimmune Therapeutics plc
1.0750
+1.42%
 
ATRA Atara Biotherapeutics, Inc.
0.6900
-1.40%